References

Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National epidemiologic survey on alcohol and related conditions

10.1001/archpsyc.61.8.807 · ExternalCitation · doi-reference

Diagnosis and pharmacotherapy of alcohol use disorder: A review

10.1001/jama.2018.11406 · ExternalCitation · doi-reference

Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: A randomized controlled trial

10.1001/jama.287.19.2559 · ExternalCitation · doi-reference

Association of high-intensity binge drinking with lipid and liver function enzyme levels

10.1001/jamanetworkopen.2019.5844 · ExternalCitation · doi-reference

Association of antihypertensive drug target genes with psychiatric disorders: A Mendelian randomization study

10.1001/jamapsychiatry.2021.0005 · ExternalCitation · doi-reference

Repurposing semaglutide and liraglutide for alcohol use disorder

10.1001/jamapsychiatry.2024.3599 · ExternalCitation · doi-reference

Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial

10.1001/jamapsychiatry.2024.4789 · ExternalCitation · doi-reference

Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery

10.1001/jamasurg.2013.700 · ExternalCitation · doi-reference

An age-period-cohort approach to studying long-term trends in obesity and overweight in England (1992–2019)

10.1002/oby.23657 · ExternalCitation · doi-reference

Efficacy and safety of GLP-1 receptor agonists, dual agonists, and Retatrutide for weight loss in adults with overweight or obesity: A bayesian NMA

10.1002/oby.24360 · ExternalCitation · doi-reference

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis

10.1007/s00125-022-05715-4 · ExternalCitation · doi-reference

Semaglutide, tirzepatide, and Retatrutide attenuate the interoceptive effects of alcohol in male and female rats

10.1007/s00213-025-06854-3 · ExternalCitation · doi-reference

Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats

10.1007/s11011-014-9627-z · ExternalCitation · doi-reference

Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs

10.1007/s11033-025-10648-3 · ExternalCitation · doi-reference

Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers

10.1007/s12020-020-02394-2 · ExternalCitation · doi-reference

The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SurPASS clinical trials

10.1007/s13300-020-00981-0 · ExternalCitation · doi-reference

Alcohol consumption and obesity: An update

10.1007/s13679-014-0129-4 · ExternalCitation · doi-reference

Quantifying alcohol consumption: Self-report, transdermal assessment, and prediction of dependence symptoms

10.1016/j.addbeh.2015.06.042 · ExternalCitation · doi-reference

Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease

10.1016/j.alcohol.2020.07.010 · ExternalCitation · doi-reference

A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus

10.1016/j.appet.2022.106022 · ExternalCitation · doi-reference

Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats

10.1016/j.bbr.2021.113726 · ExternalCitation · doi-reference

A brainstem circuit for nausea suppression

10.1016/j.celrep.2022.110953 · ExternalCitation · doi-reference

Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease

10.1016/j.cgh.2018.11.033 · ExternalCitation · doi-reference

The impact of obesity and metabolic syndrome on alcoholic liver disease

10.1016/j.cld.2013.09.006 · ExternalCitation · doi-reference

Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake

10.1016/j.cmet.2019.07.013 · ExternalCitation · doi-reference

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-Chemistry, physiology, and clinical applications

10.1016/j.cmet.2023.07.010 · ExternalCitation · doi-reference

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor

10.1016/j.cmet.2024.05.010 · ExternalCitation · doi-reference

The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice

10.1016/j.cmet.2024.11.003 · ExternalCitation · doi-reference

Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats

10.1016/j.ebiom.2023.104642 · ExternalCitation · doi-reference

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice

10.1016/j.ejphar.2010.10.059 · ExternalCitation · doi-reference

Largely overlapping neuronal substrates of reactivity to drug, gambling, food and sexual cues: A comprehensive meta-analysis

10.1016/j.euroneuro.2016.06.013 · ExternalCitation · doi-reference

Alcohol-associated liver disease: A review

10.1016/j.gande.2025.01.003 · ExternalCitation · doi-reference

Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

10.1016/j.jad.2016.09.056 · ExternalCitation · doi-reference

Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease

10.1016/j.jhep.2022.08.030 · ExternalCitation · doi-reference

Global burden of liver disease: 2023 update

10.1016/j.jhep.2023.03.017 · ExternalCitation · doi-reference

Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease

10.1016/j.jhep.2024.11.028 · ExternalCitation · doi-reference

The effects of wine consumption and lipid profile: A systematic review and meta-analysis of clinical trials

10.1016/j.jnha.2025.100539 · ExternalCitation · doi-reference

Glucose-dependent insulinotropic polypeptide (GIP)

10.1016/j.molmet.2025.102118 · ExternalCitation · doi-reference

Glucose-dependent insulinotropic peptide receptor expression in the hippocampus and neocortex of mesial temporal lobe epilepsy patients and rats undergoing pilocarpine induced status epilepticus

10.1016/j.peptides.2010.12.010 · ExternalCitation · doi-reference

GLP-1 and GIP receptor signaling in beta cells—A review of receptor interactions and co-stimulation

10.1016/j.peptides.2022.170749 · ExternalCitation · doi-reference

GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells

10.1016/j.peptides.2024.171179 · ExternalCitation · doi-reference

GIP-derived GIP receptor antagonists—A review of their role in GIP receptor pharmacology

10.1016/j.peptides.2024.171212 · ExternalCitation · doi-reference

Treatment approaches for alcohol use disorder with metabolic dysfunction

10.1016/j.pharmthera.2025.108957 · ExternalCitation · doi-reference

IUPHAR review—Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target

10.1016/j.phrs.2024.107312 · ExternalCitation · doi-reference

The elimination rates of intact GIP as well as its primary metabolite, GIP 3–42, are similar in type 2 diabetic patients and healthy subjects

10.1016/j.regpep.2006.07.007 · ExternalCitation · doi-reference

Metabolism disrupting chemicals and metabolic disorders

10.1016/j.reprotox.2016.10.001 · ExternalCitation · doi-reference

The unexpected role of GIP in transforming obesity treatment

10.1016/j.tem.2024.07.022 · ExternalCitation · doi-reference

Alcohol use and burden for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016

10.1016/s0140-6736(18)31310-2 · ExternalCitation · doi-reference

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: A randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(26)00305-3 · ExternalCitation · doi-reference

Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): A randomised, double-blind, placebo-controlled trial

10.1016/s2213-8587(19)30157-3 · ExternalCitation · doi-reference

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

10.1016/s2213-8587(22)00070-5 · ExternalCitation · doi-reference

Neurobiology of addiction: A neurocircuitry analysis

10.1016/s2215-0366(16)00104-8 · ExternalCitation · doi-reference

Psychiatric comorbidities in alcohol use disorder

10.1016/s2215-0366(19)30222-6 · ExternalCitation · doi-reference

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis

10.1016/s2215-0366(19)30416-x · ExternalCitation · doi-reference

Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019–40: A modelling study

10.1016/s2468-2667(20)30062-1 · ExternalCitation · doi-reference

A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: Potential therapeutic strategy for alcohol use disorder

10.1017/neu.2025.6 · ExternalCitation · doi-reference

Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice

10.1037/pha0000620 · ExternalCitation · doi-reference

Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117)

10.1038/mp.2017.153 · ExternalCitation · doi-reference

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

10.1038/nm727 · ExternalCitation · doi-reference

Signalling from the periphery to the brain that regulates energy homeostasis

10.1038/nrn.2018.8 · ExternalCitation · doi-reference

Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: A multi-ancestry drug-target Mendelian randomization study

10.1038/s41380-025-03199-3 · ExternalCitation · doi-reference

Crosstalk between alcohol use disorder and obesity: Two sides of the same coin?

10.1038/s41380-025-03259-8 · ExternalCitation · doi-reference

Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy

10.1038/s41392-024-01931-z · ExternalCitation · doi-reference

Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics

10.1038/s41467-020-14309-w · ExternalCitation · doi-reference

Genetic drug target validation using Mendelian randomisation

10.1038/s41467-020-16969-0 · ExternalCitation · doi-reference

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

10.1038/s41467-020-18751-8 · ExternalCitation · doi-reference

Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

10.1038/s41467-024-48780-6 · ExternalCitation · doi-reference

Whole exome sequencing analysis identifies genes for alcohol consumption

10.1038/s41467-024-50132-3 · ExternalCitation · doi-reference

A brain reward circuit inhibited by next-generation weight-loss drugs in mice

10.1038/s41586-026-10444-4 · ExternalCitation · doi-reference

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders

10.1038/s41591-023-02634-8 · ExternalCitation · doi-reference

Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals

10.1038/s41591-023-02653-5 · ExternalCitation · doi-reference

Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes

10.1038/s41598-019-42770-1 · ExternalCitation · doi-reference

Prevalence and associations of metabolic syndrome in patients with alcohol use disorder

10.1038/s41598-022-06010-3 · ExternalCitation · doi-reference

Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use

10.1038/s41598-022-17190-3 · ExternalCitation · doi-reference

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity

10.1038/s41598-023-48267-2 · ExternalCitation · doi-reference

Mendelian randomization

10.1038/s43586-021-00092-5 · ExternalCitation · doi-reference

Multivariate genome-wide analysis of aging-related traits identifies novel loci and new drug targets for healthy aging

10.1038/s43587-023-00455-5 · ExternalCitation · doi-reference

An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders

10.1038/s44220-025-00390-x · ExternalCitation · doi-reference

The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: Evidence from human genetic association studies and a mouse model of alcohol dependence

10.1038/tp.2015.68 · ExternalCitation · doi-reference

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): Functional analysis of lipid metabolism pathways

10.1042/cs20220572 · ExternalCitation · doi-reference

Biology of incretins: GLP-1 and GIP

10.1053/j.gastro.2007.03.054 · ExternalCitation · doi-reference

Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis

10.1053/j.gastro.2025.02.044 · ExternalCitation · doi-reference

Drinking and obesity: Alcoholic liver disease/nonalcoholic fatty liver disease interactions

10.1055/s-0040-1701443 · ExternalCitation · doi-reference

Tirzepatide for metabolic dysfunction–associated steatohepatitis with liver fibrosis

10.1056/nejmoa2401943 · ExternalCitation · doi-reference

Tirzepatide as compared with semaglutide for the treatment of obesity

10.1056/nejmoa2416394 · ExternalCitation · doi-reference

Once-monthly Maridebart cafraglutide for the treatment of obesity — A Phase 2 trial

10.1056/nejmoa2504214 · ExternalCitation · doi-reference

The prevalence of metabolic syndrome in alcohol use disorders: A systematic review and meta-analysis

10.1093/alcalc/agw040 · ExternalCitation · doi-reference

GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells

10.1093/ejendo/lvac004 · ExternalCitation · doi-reference

Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies

10.1093/eurjpc/zwad050 · ExternalCitation · doi-reference

Bariatric surgery and risk of alcohol use disorder: A register-based cohort study

10.1093/ije/dyaa147 · ExternalCitation · doi-reference

Metabolic profiling of alcohol consumption in 9778 young adults

10.1093/ije/dyw175 · ExternalCitation · doi-reference

Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats

10.1097/fbp.0000000000000609 · ExternalCitation · doi-reference

Transforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists

10.1097/hc9.0000000000000561 · ExternalCitation · doi-reference

Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats

10.1097/wnr.0000000000001071 · ExternalCitation · doi-reference

Alcohol use disorder with metabolic dysfunction is associated with adverse health impacts in a United States clinical setting

10.1111/adb.70128 · ExternalCitation · doi-reference

Alcohol use disorder and the gut

10.1111/add.15147 · ExternalCitation · doi-reference

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis

10.1111/add.16679 · ExternalCitation · doi-reference

Impact of GLP-1 receptor agonists on alcohol-related liver disease development and progression in alcohol use disorder

10.1111/apt.70007 · ExternalCitation · doi-reference

Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study

10.1111/bcpt.13776 · ExternalCitation · doi-reference

Effects of GLP-1 receptor agonists in alcohol use disorder

10.1111/bcpt.70004 · ExternalCitation · doi-reference

The role of nucleus of the solitary tract glucagon-like peptide-1 and prolactin-releasing peptide neurons in stress: Anatomy, physiology and cellular interactions

10.1111/bph.15576 · ExternalCitation · doi-reference

The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

10.1111/bph.15677 · ExternalCitation · doi-reference

Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution

10.1111/cts.13122 · ExternalCitation · doi-reference

The role of alcohol use in the aetiology and progression of liver disease: A narrative review and a quantification

10.1111/dar.13286 · ExternalCitation · doi-reference

Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis

10.1111/dom.13522 · ExternalCitation · doi-reference

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial

10.1111/dom.14334 · ExternalCitation · doi-reference

The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

10.1111/dom.15216 · ExternalCitation · doi-reference

Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial

10.1111/dom.70006 · ExternalCitation · doi-reference

Changing landscape of alcohol-associated liver disease in younger individuals, women, and ethnic minorities

10.1111/liv.15933 · ExternalCitation · doi-reference

Scoping review of assessment tools for, magnitudes of and factors associated with problem drinking in population-based studies

10.1136/bmjopen-2023-080657 · ExternalCitation · doi-reference

Antipsychotics and glucose metabolism: How brain and body collide

10.1152/ajpendo.00164.2018 · ExternalCitation · doi-reference

Glucose-dependent insulinotropic polypeptide regulates dipeptide absorption in mouse jejunum

10.1152/ajpgi.00098.2013 · ExternalCitation · doi-reference

Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis

10.1152/jn.00866.2010 · ExternalCitation · doi-reference

Recent advances in alcohol metabolism: From the gut to the brain

10.1152/physrev.00053.2024 · ExternalCitation · doi-reference

Alcohol use and cardiovascular disease: A scientific statement from the American Heart Association

10.1161/cir.0000000000001341 · ExternalCitation · doi-reference

Sex-specific associations between alcohol consumption and incidence of hypertension: A systematic review and meta-analysis of cohort studies

10.1161/jaha.117.008202 · ExternalCitation · doi-reference

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

10.1172/jci.insight.140532 · ExternalCitation · doi-reference

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

10.1172/jci.insight.159863 · ExternalCitation · doi-reference

Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding

10.1172/jci.insight.164921 · ExternalCitation · doi-reference

Effects of dulaglutide on alcohol consumption during smoking cessation

10.1172/jci.insight.170419 · ExternalCitation · doi-reference

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

10.1172/jci.insight.170671 · ExternalCitation · doi-reference

Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

10.1172/jci116186 · ExternalCitation · doi-reference

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

10.1172/jci146353 · ExternalCitation · doi-reference

Alcohol-associated liver disease

10.1172/jci176345 · ExternalCitation · doi-reference

Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits

10.1172/jci194751 · ExternalCitation · doi-reference

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: The CHOICE prospective observational study

10.1186/1477-7525-11-217 · ExternalCitation · doi-reference

Burden of diseases attributable to excess body weight in 204 countries and territories, 1990–2019

10.1186/s12937-025-01082-z · ExternalCitation · doi-reference

Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease

10.1186/s12967-023-04166-8 · ExternalCitation · doi-reference

Minireview: Finding the sweet spot: Peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis

10.1210/en.2009-0220 · ExternalCitation · doi-reference

Functional GIP receptors are present on adipocytes

10.1210/endo.139.9.6288 · ExternalCitation · doi-reference

Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance

10.1210/jc.2013-3350 · ExternalCitation · doi-reference

GLP1 receptor agonists reduce fluid intake in primary polydipsia

10.1210/jendso/bvab048.1052 · ExternalCitation · doi-reference

Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study

10.1371/journal.pmed.1003410 · ExternalCitation · doi-reference

Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward

10.1371/journal.pone.0061965 · ExternalCitation · doi-reference

Prevalence patterns of overweight and obesity in the world: An age-period-cohort analysis

10.1371/journal.pone.0324733 · ExternalCitation · doi-reference

Alcohol consumption and risk of liver cirrhosis: A systematic review and meta-analysis

10.14309/ajg.0000000000000340 · ExternalCitation · doi-reference

Progression of alcoholic and non-alcoholic steatohepatitis: Common metabolic aspects of innate immune system and oxidative stress

10.2133/dmpk.dmpk-10-rv-087 · ExternalCitation · doi-reference

Obesity and its comorbidities: Current treatment options, emerging biological mechanisms, future perspectives and challenges

10.2147/dmso.s540103 · ExternalCitation · doi-reference

A complex interplay between nutrition and alcohol use disorder: Implications for breaking the vicious cycle

10.2174/0113816128292367240510111746 · ExternalCitation · doi-reference

CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults

10.2337/db23-75-lb · ExternalCitation · doi-reference

1861-LB: Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in obese adults—A Phase 2 trial

10.2337/db24-1861-lb · ExternalCitation · doi-reference

142-OR: Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HDM1005)—A Phase I, randomized, double-blind, placebo-controlled, single and multiple dose-escalation study

10.2337/db25-142-or · ExternalCitation · doi-reference

Food addiction: A common neurobiological mechanism with drug abuse

10.2741/4618 · ExternalCitation · doi-reference

Distinct identity of GLP-1R, GLP-2R, and GIPR expressing cells and signaling circuits within the gastrointestinal tract

10.3389/fcell.2021.703966 · ExternalCitation · doi-reference

Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes

10.3389/fendo.2022.838410 · ExternalCitation · doi-reference

Anatomical and functional characterization of central amygdala glucagon-like peptide 1 receptor expressing neurons

10.3389/fnbeh.2021.724030 · ExternalCitation · doi-reference

Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines

10.3389/fnins.2022.1042442 · ExternalCitation · doi-reference

Genetic variability of incretin receptors and alcohol dependence: A pilot study

10.3389/fnmol.2022.908948 · ExternalCitation · doi-reference

Targeting unmet clinical needs in the treatment of alcohol use disorder

10.3389/fpsyt.2022.767506 · ExternalCitation · doi-reference

Effect of glucagon-like Peptide-1 receptor agonists on cardio-metabolic risk factors among obese/overweight individuals treated with antipsychotic drug classes: An updated systematic review and meta-analysis of randomized controlled trials

10.3390/biomedicines11030669 · ExternalCitation · doi-reference

GLP-1 analogues in the neurobiology of addiction: Translational insights and therapeutic perspectives

10.3390/ijms26115338 · ExternalCitation · doi-reference

Old and new biomarkers of alcohol abuse: Narrative review

10.3390/jcm12062124 · ExternalCitation · doi-reference

Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: A propensity score-matched analysis

10.3390/jcm14030944 · ExternalCitation · doi-reference

Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: Opportunities for a tailored approach to diabetes and obesity care

10.3390/jpm12030454 · ExternalCitation · doi-reference

Glucagon-like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress

10.3390/nu12113304 · ExternalCitation · doi-reference

Alcohol’s impact on the gut and liver

10.3390/nu13093170 · ExternalCitation · doi-reference

Chronic diseases and conditions related to alcohol use

10.35946/arcr.v35.2.06 · ExternalCitation · doi-reference

Pharmacotherapy for co-occurring alcohol use disorder and post-traumatic stress disorder: Targeting the opioidergic, noradrenergic, serotonergic, and GABAergic/glutamatergic systems

10.35946/arcr.v39.2.09 · ExternalCitation · doi-reference

Chronic alcohol consumption potentiates the development of diabetes through pancreatic β-cell dysfunction

10.4331/wjbc.v6.i1.1 · ExternalCitation · doi-reference

Efficacy and safety of tirzepatide in type 2 diabetes and obesity management

10.7570/jomes22067 · ExternalCitation · doi-reference